What is the drug class of Nifedipine (Calcium Channel Blocker)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Nifedipine is a calcium channel blocker, specifically a dihydropyridine, which works by blocking calcium channels in blood vessel walls and heart muscle, causing relaxation of these tissues and leading to vasodilation. This classification is based on the most recent and highest quality study available, which provides a comprehensive overview of calcium channel blockers and their properties 1. The dihydropyridine subclass, to which nifedipine belongs, has high selectivity for L-type channels in the vasculature and produces a decrease in coronary and systemic vascular resistance, exerting an antianginal action by reducing oxygen demand.

Key Properties of Nifedipine

  • Nifedipine is primarily used to treat hypertension (high blood pressure) and angina (chest pain) 1.
  • Common dosages include immediate-release forms and extended-release formulations, with the latter generally preferred due to reduced risk of rapid drops in blood pressure and reflex tachycardia 1.
  • Common side effects include headache, flushing, dizziness, and peripheral edema (swelling in the legs and ankles) 1.
  • Grapefruit juice should be avoided when taking nifedipine as it can increase drug levels and side effects by inhibiting metabolism of the medication.

Clinical Considerations

  • Immediate-release nifedipine should not be administered to patients with non-ST-elevation acute coronary syndromes (NSTE-ACS) in the absence of beta-blocker therapy due to increased risk of harm 1.
  • Long-acting preparations of nifedipine may be useful in older patients with systolic hypertension 1.
  • The use of nifedipine and other calcium channel blockers should be guided by the most recent clinical guidelines and evidence-based practice, taking into account individual patient needs and medical history 1.

From the FDA Drug Label

Nifedipine is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist) Nifedipine extended-release tablets, USP are an extended release tablet dosage form of the calcium channel blocker nifedipine.

The drug class of Nifedipine is a Calcium Channel Blocker 2 2.

  • Key words: Calcium Channel Blocker, calcium ion influx inhibitor
  • Main idea: Nifedipine belongs to the class of drugs known as calcium channel blockers.

From the Research

Drug Class of Nifedipine

  • Nifedipine is classified as a Calcium Channel Blocker (CCB) 3, 4, 5, 6, 7
  • Specifically, it belongs to the dihydropyridine class of CCBs, which primarily act as vasodilators 3, 4, 5, 6, 7

Mechanism of Action

  • Nifedipine works by blocking the L-type calcium receptors in the peripheral vasculature, leading to arterial vasodilation 7
  • At high concentrations, such as in overdoses, nifedipine can lose specificity for its receptors and show all manifestations of toxicity, including bradycardia, peripheral vasodilation, and hypotension 7

Clinical Uses

  • Nifedipine is used in the treatment of hypertension, angina, and supraventricular tachycardia 3, 4, 5, 6
  • It is also used to prevent cardiovascular morbidity and mortality associated with uncontrolled hypertension, including stroke 5, 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Calcium channel blockers.

AACN clinical issues in critical care nursing, 1992

Research

The role of existing and newer calcium channel blockers in the treatment of hypertension.

Journal of clinical hypertension (Greenwich, Conn.), 2004

Research

Use of nifedipine in the treatment of hypertension.

Expert review of cardiovascular therapy, 2005

Research

Calcium Channel Blocker Overdose.

Journal of education & teaching in emergency medicine, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.